Urgent.News

What's breaking now, across thousands of outlets.

AI

Evogene Q3 2026 slides highlight AI drug progress amid 75% revenue drop

Evogene Q3 2026 slides highlight AI drug progress amid 75% revenue drop

Evogene Ltd. reported a 75% decline in Q3 2026 revenue, sliding to $822,000 from $3.2 million a year earlier, alongside a widening loss of $10.5 million, up from $2.5 million in the same period last year. Despite these financial challenges, the company highlighted significant progress in its AI-driven drug discovery and agricultural chemical programs.

The ChemPass AI platform showcased promising results in developing novel small molecules for treating acute graft-versus-host disease and fungicide candidates for wheat disease. However, the company's financial position remains precarious, with total assets dropping to $12.6 million and an expanded accumulated deficit of $293.0 million.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in AI

More from Thursday 19 November →